Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | PTEN dec exp |
Therapy | Docetaxel + Ipatasertib |
Indication/Tumor Type | triple-receptor negative breast cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PTEN dec exp | triple-receptor negative breast cancer | sensitive | Docetaxel + Ipatasertib | Preclinical - Pdx | Actionable | In a preclinical study, the combination of Ipatasertib (GDC-0068) and Taxotere (docetaxel) inhibited tumor growth in a patient-derived xenograft (PDX) model of triple-negative breast cancer with low PTEN expression, and demonstrated increased activity over either agent alone (PMID: 32205017). | 32205017 |
PubMed Id | Reference Title | Details |
---|---|---|
(32205017) | Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors. | Full reference... |